Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.

Wolff AC, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman PA, Webb NL, Baker SD.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3589-97.

2.

Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.

Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S, Chander MC, Baker SD, He L, Horwitz SB, Swindell CS.

Clin Cancer Res. 2001 Oct;7(10):3229-38.

3.

Tumor targeting by conjugation of DHA to paclitaxel.

Bradley MO, Swindell CS, Anthony FH, Witman PA, Devanesan P, Webb NL, Baker SD, Wolff AC, Donehower RC.

J Control Release. 2001 Jul 6;74(1-3):233-6.

PMID:
11489499
4.

New product opportunities with DRGs.

Anthony FH.

Hosp Pharm. 1985 Jan;20(1):10-1.

PMID:
10310980
5.

Fusion of dipalmitoylphosphatidylcholine vesicles at 4 degrees C.

Wong M, Anthony FH, Tillack TW, Thompson TE.

Biochemistry. 1982 Aug 17;21(17):4126-32.

PMID:
6896998
6.

Modification of a vibrating-tube density meter for precise temperature scanning.

Anthony FH, Biltonen RL, Freire E.

Anal Biochem. 1981 Sep 1;116(1):161-7. No abstract available.

PMID:
7304976

Supplemental Content

Loading ...
Support Center